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Summary Background This phase I, dose-finding study
evaluated the maximum tolerated dose (MTD), safety, phar-
macokinetics, and antitumor activity of sunitinib plus S-1/cis-
platin in Japanese patients with advanced/metastatic gastric
cancer. Patients and methods Patients received oral sunitinib
on a continuous daily dosing (CDD) or 2-weeks-on/2-weeks-
off schedule (Schedule 2/2; 25 mg/day or 37.5 mg/day), plus
S-1 (80–120 mg/day)/cisplatin 60 mg/m2. Results Twenty-
seven patients received treatment, including 26 patients
treated per protocol (sunitinib 25 mg/day CDD schedule,
n=4; sunitinib 25 mg/day Schedule 2/2, n=16 [dose-lim-
iting toxicity (DLT) cohort, n=6 plus expansion cohort, n=
10]; sunitinib 37.5 mg/day Schedule 2/2, n=6). One patient
erroneously self-administered sunitinib 12.5 mg/day and
was excluded from the analyses. The MTD was sunitinib
25 mg/day on Schedule 2/2. DLTs were reported for: 2/4
patients given sunitinib 25 mg/day on the CDD schedule;
1/6 patients administered sunitinib 25 mg/day on Schedule
2/2 (grade [G] 3 neutropenic infection, G4 thrombocytope-
nia, and S-1 dose interruption ≥5 days), and 3/6 patients
given sunitinib 37.5 mg/day on Schedule 2/2. Results
below are for the overall MTD cohort (n=16). The most
frequently reported G3/4 adverse events were neutrope-
nia (93.8 %) and leukopenia (75.0 %). The objective
response rate was 37.5 %; six additional patients expe-
rienced no disease progression for ≥24 weeks. Median
progression-free survival was 12.5 months. No pharma-
cokinetic drug–drug interactions were observed between
sunitinib/S-1/cisplatin and S-1/cisplatin. Conclusions The
MTD of sunitinib was 25 mg/day on Schedule 2/2 combined
with cisplatin/S-1 in patients with advanced/metastatic gastric
cancer. This regimen had a manageable safety profile and
preliminary antitumor activity.
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Introduction
Gastric cancer is the second most common cause of cancer-
related death worldwide, with more than 730,000 deaths
estimated to have occurred in 2008 [1]. Globally, the
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5-year survival rate for gastric cancer is approximately 20 %
[2], and most patients present with advanced, non-resectable
disease [3–5].
Despite recent advances in the treatment for gastric cancer
[6], a standard chemotherapy regimen has not been
established for recurrent or unresectable advanced gastric
cancer; combination chemotherapy is associated with signifi-
cant survival and quality of life advantages, compared with
best supportive care [7, 8]. The use of a 5-fluorouracil (5-FU)-
based regimen in combination with a platinum analog is the
most widely accepted first-line treatment regimen, although
combination therapy does have a higher associated toxicity
burden compared with single-agent chemotherapy [8].
Blockade of receptors such as vascular endothelial
growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR) has been shown to inhibit
tumor-related angiogenesis and tumor growth [9, 10]. Not
only are these receptors expressed in gastric cancers but they
are known to have direct effects on the growth and metas-
tasis of this disease [9–14].
Sunitinib malate (SUTENT®; Pfizer Inc., New York, NY,
USA) is an oral, multitargeted, tyrosine kinase inhibitor of
VEGFRs 1–3, PDGFR-α and -β, and other receptors [15–17].
Sunitinib is approved multinationally for the treatment of
unresectable and/or metastatic imatinib-resistant/-intolerant
gastrointestinal stromal tumor, advanced/metastatic renal cell
carcinoma, and unresectable or metastatic, well-differentiated
pancreatic neuroendocrine tumors. Phase II study results in
advanced gastric cancer have shown that sunitinib had activity
as a single-agent; progression-free survival (PFS) was
2.3 months and overall survival was 6.8 months in the
second-line setting [18].
In preclinical tumor models, sunitinib has been shown to
enhance the antitumor activity of 5-FU and cisplatin,
suggesting that sunitinib might enhance the effect of che-
motherapy in cancer patients [19, 20]. In the First-Line
Advanced Gastric Cancer Study (FLAGS), the combination
of S-1, an oral derivative of 5-FU, and cisplatin was found
to be effective when administered as a 3-week on/1-week
off regimen (Schedule 3/1) [21]. Therefore, this phase I,
dose-finding study was conducted to determine the maxi-
mum tolerated dose (MTD) and overall safety profile of
sunitinib plus S-1 and cisplatin in Japanese patients with
advanced/metastatic gastric cancer. Tolerability, pharmaco-
kinetics (PK), and antitumor activity were also evaluated.
Materials and methods
Study population
Patients (male or female) eligible for inclusion in this study
were aged ≥20 years, had an Eastern Cooperative Oncology
Group performance status of 0 or 1, adequate organ func-
tion, and histologically or cytologically confirmed Stage IV
gastric adenocarcinoma or gastroesophageal junction ade-
nocarcinoma not amenable to surgery or radiation. Prior
adjuvant therapy was permitted with a recurrence-free inter-
val of >3 months after the completion of adjuvant therapy.
Prior chemotherapy in the advanced/metastatic setting was
not permitted; one regimen of chemotherapy, such as S-1
monotherapy, without progressive disease was allowed if
the duration of treatment was less than 4 weeks.
Exclusion criteria included central nervous system (CNS)
metastases, carcinomatous meningitis, or uncontrolled hy-
pertension (blood pressure >150/100 mmHg). Patients with
severe/unstable angina, myocardial infarction, coronary ar-
tery bypass graft, symptomatic congestive heart failure,
cerebrovascular accident, including transient ischemic at-
tack, or pulmonary embolism within 12 months prior to
starting study treatment were also excluded.
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Good Clinical Practice
guidelines, the declaration of Helsinki, and applicable local
regulatory requirements and laws. Approval from the insti-
tutional review board or independent ethics committee with
the appropriate jurisdiction was required for each participat-
ing investigator/center. Written informed consent was
obtained from all patients.
Study design
This was a phase I, open-label, dose-finding study of sunitinib
in combination with S-1 and cisplatin in patients with
advanced/metastatic gastric cancer (NCT00553696). Patients
received open-label, oral S-1 at a starting dose of 80–
120 mg/day (based on body surface area) on Schedule 3/1
and a cisplatin 60 mg/m2 infusion on day 1 that was repeated
every 28 days. Patients were allocated to different doses of
oral sunitinib based on a 3+3 design. Initially, sunitinib was
planned to be administered on a continuous daily dosing
(CDD) schedule or on Schedule 3/1. After four patients re-
ceived treatment in the CDD arm, the protocol was revised to
use a 2-week-on/2-week-off schedule (Schedule 2/2), in-
stead of Schedule 3/1, due to the pattern of adverse events
(AEs). Patients received sunitinib 25 mg/day on a CDD
schedule, or 25 mg/day or 37.5 mg/day on Schedule 2/2 in
4-weekcycles (Fig. 1).
Initially, three patients were enrolled to receive sunitinib
25 mg/day on the CDD schedule in combination with S-1
and cisplatin 60 mg/m2. If no patients experienced a dose-
limiting toxicity (DLT) in cycle 1 then patients would be
enrolled to the next highest dose level. If no more than one
of the initial three patients experienced a DLT within cycle
1, then the cohort was expanded to a total of six patients. If
no more than one of these six patients experienced a DLT,
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then patients would be enrolled at the next highest dose
level.
The MTD was defined as the highest dose cohort
where 0/3 or ≤1/6 patients experienced a DLT, with the
next highest dose having at least 2/3 or 2/6 patients who
experienced a DLT. DLTs are defined in Table 1. In this
study, the MTD level was confirmed by expanding en-
rollment to include up to 10 additional patients with
advanced/metastatic disease in order to obtain additional
safety data for the combination treatment. It was antici-
pated that a total of approximately 30 patients would be
enrolled in this study.
Dose modifications of sunitinib were not allowed until a
DLT was reached. Once dose reduction occurred due to
study drug-related toxicity, the dose was not re-escalated.
Patients could undergo a maximum of two dose reductions
of either S-1 and/or cisplatin. However, patients requiring
more than two dose reductions of S-1 or sunitinib were
withdrawn from the study. Additionally, patients with >1
missed cisplatin dose were withdrawn. Treatment was con-
tinued for 8 cycles or until disease progression, unaccept-
able toxicity, or withdrawal of patient consent.
The primary endpoint was the assessment of first-cycle
DLTs for sunitinib plus S-1 and cisplatin. Secondary end-
points included overall safety, tumor response, PFS, and PK.
Assessments
Patients were evaluable for DLT assessment if they received
all day 1 chemotherapy and ≥80 % of their sunitinib doses
and S-1 doses. Those who could not receive ≥80 % of their
doses for reasons other than a DLT were excluded from the
DLT evaluation. Tumor assessment was performed at base-
line, on day 22 of cycle 1, and every 4 weeks thereafter until
radiographic-confirmed disease progression or end of treat-
ment scan. Objective tumor response in patients with at least
one target lesion was measured using the Response Evalu-
ation Criteria in Solid Tumors (RECIST) guidelines [22]
Fig. 1 Treatment schema.
aSunitinib dose withheld on
cycle 1 day 1 to enable
pharmacokinetic analysis of S-1
and cisplatin. bS-1 and cisplatin
dose withheld on cycle 1 day 1
to enable pharmacokinetic
analysis of sunitinib. BID twice
daily; Schedule 2/2 2 weeks on
treatment followed by 2 weeks
off treatment
Table 1 Definition of DLT
Category DLT criteria
Hematologic Grade 4 neutropenia lasting ≥7 days
Grade ≥3 febrile neutropenia
Grade ≥3 neutropenic infection
Grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding
Non-hematologica Grade 3 toxicities lasting ≥7 days
Grade 4 non-hematologic toxicity
Grade 3/4 nausea, vomiting or diarrhea persisting despite maximum supportive therapy
Missed/delayed dose due to toxicity Break from sunitinib dose ≥6/28 days on the CDD schedule or ≥3/14 days on Schedule 2/2
Break from S-1 dose ≥5/21 days per cycle
Delay of >3 weeks in starting the second treatment cycle
CDD continuous daily dosing; DLT dose-limiting toxicity; Schedule 2/2 2 weeks on treatment followed by 2 weeks off treatment
a Exceptions: hyperamylasemia or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia; asymptomatic
hypertension with adequately controlled blood pressure
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and confirmed no sooner than 4 weeks after the initial
documentation of response.
Safety was assessed at regular intervals (during cycle 1
on days 1, 2, 8, 15, and 22; during cycles 2–8 on days 1, 2,
and 21; and during cycles ≥9 on days 1 and 21). AEs were
monitored during the study and graded using the National
Cancer Institute Common Terminology for Adverse Events
version 3.0 clinical assessments, including laboratory test-
ing for blood hematology and serum chemistry.
To investigate PK drug–drug interactions, full PK pro-
files of sunitinib, its active metabolite SU12662, S-1 (5-FU,
tegafur) and cisplatin (total and free) were assessed in all
cohorts comprising the 3+3 design, and in the MTD expan-
sion cohort. Blood samples for analyses of cisplatin and S-1
were collected on cycle 1 days 1–2 (S-1 and cisplatin),
before starting sunitinib dosing on day 2, and on cycle 2 days
1–2 (in combination with sunitinib) in the MTD cohort. In
the expansion cohort, blood samples for the analyses of
sunitinib and SU12662 were collected on cycle 1 days 1–2
(sunitinib alone), prior to administration of S-1 and cisplatin
on day 2, and cycle 2 days 1–2 (in combination with S-1 and
cisplatin). PK parameters were calculated using non-
compartmental methods.
Trough plasma concentrations of sunitinib and SU12662
were obtained at steady state on cycles 1–3 days 21–22 for
the CDD schedule, and cycles 1–3 days 14–15 for Schedule
2/2. Blood samples were obtained before the administration
of sunitinib and S-1.
On the day of cisplatin PK sampling, blood was drawn
pre-dose (before administration of cisplatin, S-1 or
sunitinib) and at 0.5, 1, 2, 8, and 22 h after completing
infusion. Samples for evaluation of sunitinib, SU12662,
and S-1 PK were obtained pre-dose (before administration
of either S-1 or sunitinib) and at 1, 2, 4, 6, 8, and 10 h post-
dose (before dosing of S-1). For sunitinib and SU12662, a
sample was also obtained 24 h post-dose.
Plasma samples were analyzed for sunitinib and
SU12662 concentrations by Bioanalytical Systems Inc.
(USA) using a validated high-performance liquid chroma-
tography tandem mass spectrometric (HPLC-MS/MS) meth-
od. Tegafur and 5-FU plasma concentrations were also
determined using a validated HPLC-MS/MS method by
Tandem Labs (USA). Cisplatin concentrations were deter-
mined in both plasma and plasma ultra filtrate samples by
Covance Laboratories Inc. (USA) using a validated Induc-
tively Coupled Plasma–Mass Spectrometric (ICP/MS)
method.
Statistical analysis
The sample size was determined on an empirical rather than
statistical basis. Assessment of 3–6 patients for each cohort
was considered adequate to characterize the safety of a
treatment regimen prior to investigation in phase II clinical
trials. It was anticipated that up to 30 patients would be
enrolled in this study.
Efficacy analyses included all patients who received at
least one protocol-specified dose of sunitinib. Descriptive
statistics were used to summarize all patient characteristics,
treatment administration/compliance, antitumor activity, and
safety; PFS was summarized using the Kaplan–Meier meth-
od. In an unplanned exploratory analysis, clinical benefit
rate (CBR; percentage of patients with a complete response,
partial response, and stable disease ≥24 weeks) and PFS




In total, 27 patients received treatment, including 26 pa-
tients treated per protocol (sunitinib 25 mg/day on the
CDD schedule, 4; sunitinib 25 mg/day on Schedule 2/2,
16 [DLT cohort, 6 plus expansion cohort, 10]; sunitinib
37.5 mg/day on Schedule 2/2, 6), and one patient who
was assigned to sunitinib 25 mg/day on Schedule 2/2 and
erroneously self-administered sunitinib 12.5 mg/day
throughout the study. The latter patient was excluded from
the efficacy analyses. One patient remained on study as of
April 2012. Demographic and baseline disease character-
istics are shown in Table 2. Overall, eight patients had
scirrhous-type disease (seven patients in the MTD cohort).
Safety and drug exposure
Twenty-seven patients were evaluable for safety. The MTD
was determined to be sunitinib 25 mg/day on Schedule 2/2
plus cisplatin and S-1, and a further 10 patients were allo-
cated to this cohort. Of the four patients who received
sunitinib 25 mg/day on the CDD schedule, two DLTs were
reported: grade 4 thrombocytopenia (n=1), and grade 4
thrombocytopenia plus grade 3 febrile neutropenia (n=1).
Subsequently, the treatment frequency was reduced to
sunitinib 25 mg/day on Schedule 2/2. In the second cohort,
one of six patients reported a DLT: grade 3 neutropenic
infection plus grade 4 thrombocytopenia and S-1 dose in-
terruption of ≥5 days. As defined in the protocol, the
sunitinib dose was then increased to 37.5 mg/day on Sched-
ule 2/2, where three of six patients experienced a DLT: grade
3 febrile neutropenia plus S-1 dose interruption of ≥5 days
(n=1), grade 4 thrombocytopenia (n=1), and grade 4 neu-
tropenia of ≥7 days (n=1).
All patients experienced at least one AE. No grade 5
AEs occurred. Serious AEs (SAEs) were reported in 13
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patients overall (48.1 %). Dose reductions due to AEs
occurred for all three drugs: sunitinib: n=8; S-1: n=7;
cisplatin: n=8. At the MTD, the median relative dose
intensity (% actual/intended dose intensity) was 80.6 %
(range, 32.4–100.0) for sunitinib (25 mg/day, Schedule
2/2), 68.2 % (35.7–85.7) for S-1, and 73.8 % (27.1–98.9)
for cisplatin. Overall, seven patients discontinued the
study treatment due to AEs, including four patients in
the MTD cohort.
In the MTD cohort (sunitinib 25 mg/day, Schedule 2/2;
n=16), the frequencies of common AEs of any grade are
presented in Table 3. Neutropenia was the most frequently
reported grade 3 or 4 AE, occurring in 15 patients (93.8 %).
In total, 75.0 % of patients in the MTD cohort experienced
grade 3 or 4 leukopenia. Fatigue, decreased appetite, nausea,
constipation, thrombocytopenia, and stomatitis were the
most common grade 1 or 2 AEs reported. In this cohort,
SAEs occurred in eight patients (50.0 %); the most frequent
SAEs were febrile neutropenia (n=3, 18.8 %) and platelet
count decreased (n=2, 12.5 %).
Pharmacokinetics
The MTD combination of sunitinib (25 mg/day, Schedule
2/2) with S-1 plus cisplatin demonstrated no changes in the
PK of sunitinib or its active metabolite (SU12662). In addi-
tion, combination treatment had no impact on the PK of
cisplatin, tegafur, 5-FU, or S-1, compared with S-1 plus
cisplatin alone (Table 4).
The mean trough plasma concentrations (Ctrough) of
sunitinib, SU12662, and total drug were 33.5 ng/mL,
13.9 ng/mL, and 47.5 ng/mL, respectively, for sunitinib
25 mg/day, and 69.9 ng/mL, 24.0 ng/mL, and 93.4 ng/mL,
respectively, for sunitinib 37.5 mg/day. These Ctrough values
suggested that plasma concentrations of sunitinib increased
in a dose-dependent manner.
Antitumor activity
All patients were evaluable for efficacy. In the MTD group
(sunitinib 25 mg/day, Schedule 2/2), 11/16 patients had
Table 2 Baseline patient characteristics
CDD schedule sunitinib 25 mg/day Schedule 2/2 sunitinib 25 mg/day Schedule 2/2 sunitinib
37.5 mg/day
All patients (n=4)a All patients (n=16)b,c Patients with scirrhous-type
disease (n=7)
All patients (n=6)d
Gender, male, n (%) 2 (50.0) 13 (81.3) 6 (85.7) 4 (66.7)
Age, years
Median 63.0 60.0 57.0 60.5
Range 44–73 31–71 31–67 28–71
ECOG performance status, n (%)
0 1 (25.0) 7 (43.8) 2 (28.6) 3 (50.0)
1 3 (75.0) 9 (56.3) 5 (71.4) 3 (50.0)
Measurable disease, n (%) 3 (75.0) 11 (68.8) 5 (71.4) 4 (66.7)
Histology, n (%)
Diffuse 2 (50.0) 9 (56.2) 6 (85.7) 2 (33.3)
Intestinal 2 (50.0) 7 (43.8) 1 (14.3) 3 (50.0)
Other 0 (0) 0 (0) 0 (0) 1e (16.7)
Prior surgery, n (%) 1 (25.0) 5 (31.3) 1 (14.3) 2 (33.3)
Prior systemic therapy, n (%)
0 2 (50.0) 16 (100.0) 7 (100.0) 5 (83.3)
1 2 (50.0) 0 (0) 0 (0) 1 (16.7)
≥2 0 (0) 0 (0) 0 (0) 0 (0)
CDD continuous daily dosing; ECOG Eastern Cooperative Oncology Group; Schedule 2/2 2 weeks on treatment followed by 2 weeks off treatment
a Includes one patient with scirrhous-type disease
b Includes 10 patients from the expansion cohort
c The subject assigned to sunitinib 25 mg/day on Schedule 2/2 who mistakenly received sunitinib 12.5 mg/day was excluded from the efficacy
analyses. At baseline, this patient had an ECOG performance status of 0, stage IV measurable intestinal disease, with 2 involved tumor sites (liver
and lymph node) and no prior surgery or systemic therapy
d No patients had scirrhous-type disease in this cohort
e This patient had mucinous histology
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measurable disease. No patients had a complete response,
and partial responses occurred in 6/11 patients (54.5 %) with
measurable disease, resulting in an overall objective re-
sponse rate (ORR) of 37.5 % (95 % confidence interval
[CI], 15.2–64.6) in 16 evaluable patients. A further six
patients experienced no disease progression for ≥24 weeks,
producing a CBR of 75.0 % (95 % CI, 47.6–92.7) among
the 16 patients. Maximum percentage reduction in target
lesion size in the 11 patients with measurable disease is
shown in Fig. 2. The CBR for patients treated at the MTD
with scirrhous-type disease was 57.1 % (95 % CI, 18.4–
90.1; 4/7 patients). Tumor response in one patient with
scirrhous-type disease is shown in Fig. 3. At the MTD,
median PFS was 12.5 months (95 % CI, 6.4–16.5) and 6-
month survival was 78.3 % (95 % CI, 56.5–100.0; Table 5;
Fig. 4). Among the seven patients with scirrhous-type dis-
ease, four of five patients who had measurable lesion had a
partial response, and median PFS was 12.5 months (95 %
CI, 10.1–13.3).
Discussion
In this study, the MTD of sunitinib in combination with S-1
(80–120 mg) plus cisplatin 60 mg/m2 was established as
25 mg/day on Schedule 2/2 in patients with advanced or
metastatic gastric cancer for whom curative therapy was not
an option. Other tested combinations included sunitinib
25 mg/day on a CDD schedule and a dose-increment from
the MTD cohort to 37.5 mg; both cohorts were discontinued
after DLTs were experienced. An additional 10 patients were
then enrolled in the MTD cohort and followed for safety,
antitumor activity, and PK parameters.
The MTD combination regimen demonstrated a manage-
able safety profile, with neutropenia and leukopenia as the
most frequently reported grade 3 or 4 AEs: 93.8 % and
75.0 %, respectively. This safety profile was also consistent
with a similar phase I dose-escalation study conducted in
Western patients with advanced gastric cancer [23]. In general,
the type of AEs was consistent with those previously reported
when 5-FU and cisplatin were administered in patients with
gastric cancer [24], although the frequency of events, partic-
ularly hematologic AEs, was greater than expected from pre-
vious studies of sunitinib in other tumor types [18, 25–28].
Previously reported mild skin reactions associated with
sunitinib, such as yellowing skin/discoloration [29], were
not observed in this study. There were no grade 3 or 4 non-
Table 3 Treatment-emergent (all-causality) adverse events in ≥30 %
of patients in the maximum tolerated dose cohort (sunitinib 25 mg/day
on Schedule 2/2+cisplatin+S-1; n=16)
Adverse event, n (%) Grade 1/2 Grade 3/4 All grades
Leukopenia 4 (25.0) 12 (75.0) 16 (100.0)
Neutropenia 1 (6.3) 15 (93.8) 16 (100.0)
Anemia 6 (37.5) 9 (56.3) 15 (93.8)
Decreased appetite 14 (87.5) 1 (6.3) 15 (93.8)
Thrombocytopenia 9 (56.3) 6 (37.5) 15 (93.8)
Fatigue 14 (87.5) 0 14 (87.5)
Nausea 14 (87.5) 0 14 (87.5)
Constipation 12 (75.0) 0 12 (75.0)
Stomatitis 9 (56.3) 0 9 (56.3)
Diarrhea 7 (43.8) 1 (6.3) 8 (50.0)
Dysgeusia 7 (43.8) 0 7 (43.8)
Pyrexia 7 (43.8) 0 7 (43.8)
Hiccups 6 (37.5) 0 6 (37.5)
Rash 5 (31.3) 0 5 (31.3)
Vomiting 5 (31.3) 0 5 (31.3)
Schedule 2/2 2 weeks on treatment followed by 2 weeks off treatment
Table 4 Pharmacokinetics in the maximum tolerated dose cohort (sunitinib 25 mg/day on Schedule 2/2+cisplatin+S-1)
Treatment Analyte n Mean Cmax ng/mL (CV%) Mean AUClast ng·h/mL (CV%)
Sunitinib alone or SP Combined Sunitinib alone or SP Combined
Sunitinib Sunitinib 7 15.8 (32.2) 16.2 (44.6) 234 (25.3) 244 (38.6)
SU12662 7 2.9 (43.6) 2.8 (49.3) 46.0 (34.2) 50.5 (50.7)
Total drug 7 18.5 (33.0) 19.0 (42.3) 280 (25.0) 294 (37.2)
S-1 Tegafur 5 1,500 (9.8) 1,688 (26.9) 8,290 (10.5) 9,163 (12.7)
5-FU 5 144 (23.5) 114 (16.5) 582 (19.3) 522 (28.0)
Cisplatin Total 5 1,794 (7.8) 1,984 (3.6) 27,478 (7.1) 31,574 (5.4)
Free 5 178 (68.3) 187 (74.6) 790 (25.8) 973 (28.3)
AUClast area under the plasma concentration–time curve from time zero until last quantifiable observation; Cmax maximum concentration; CV
coefficient of variation; 5-FU 5-fluorouracil; Schedule 2/2 2 weeks on treatment followed by 2 weeks off treatment; SP cisplatin 60 mg/m2 every
28 days+S-1 40 mg/m2 twice daily every 3/1 weeks; SU12662 sunitinib active metabolite
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hematologic events reported in ≥30 % of patients within the
MTD cohort. No new safety signals were observed for
sunitinib.
Although tumor evaluation was not the primary objective
of this study, the ORR for the MTD cohort was 37.5 %
(95 % CI, 15.2–64.6) and included responses in patients
with scirrhous-type disease. Since five of 16 patients treated
at the MTD did not have measurable disease and were
assessed as non-responders in the ORR calculation, tumor
response rates may be underestimated in our study. The
ORR at the MTD among the 11 patients with measurable
disease was 54.5 %. Median PFS was 12.5 months (95 %
CI, 6.4–16.5) in the overall MTD cohort. These results
demonstrate promising preliminary antitumor activity, com-
pared with that observed for sunitinib as a single-agent
modality in advanced gastric cancer, [18] and with the
median PFS of 6 months reported for S-1 plus cisplatin
[30]. However, our results must be interpreted with caution
given the limited sample size studied.
A multitargeted tyrosine kinase inhibitor like sunitinib
may be a promising drug for scirrhous gastric cancer. Our
preliminary results suggest that sunitinib in combination
Fig. 2 Maximum percentage
change in target lesion size in
the maximum tolerated dose
(MTD) cohort (sunitinib 25 mg/
day on Schedule 2/2+
cisplatin+S-1).a Schedule 2/2
2 weeks on treatment followed
by 2 weeks off treatment. aFive
of 16 patients receiving the
MTD did not have measurable
disease
Fig. 3 Tumor response in a
patient with scirrhous gastric
cancer who received the
maximum tolerated dose of
sunitinib (25 mg/day on
Schedule 2/2) combined with





Schedule 2/2 2 weeks on
treatment followed by 2 weeks
off treatment
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with S-1 and cisplatin might have antitumor activity in
patients with this disease type. However, as only seven of
16 patients at the MTD had scirrhous-type disease, caution
should be used when interpreting these results. Despite this
caveat, these data are encouraging, as scirrhous gastric can-
cer carries a worse prognosis than the non-scirrhous-type
[31, 32], as it is characterized by rapid cancer cell infiltration
and proliferation accompanied by extensive stromal fibrosis
[32]. The proliferative and invasive ability of scirrhous
gastric cancer cells have been shown to be closely associat-
ed with the growth factors produced by organ-specific
fibroblasts and other stromal cells [32]. Therefore, targeting
this cancer–stroma interaction using a multitargeted tyrosine
kinase inhibitor such as sunitinib could be a reasonable
treatment option for patients with scirrhous gastric cancer.
However, large randomized studies would be required to
confirm this hypothesis.
The combination of sunitinib with cisplatin plus S-1
demonstrated no PK drug–drug interactions, consistent with
the different pathways of metabolism and elimination for
these drugs. These findings are consistent with those from
the phase I study with cisplatin plus 5-FU in Western pa-
tients [23]. The mean observed Ctrough plasma concentration
of 47.5 ng/mL, for total drug (sunitinib plus SU12662) at
steady-state with sunitinib 25 mg/day dosing, in the present
study suggests that optimal sunitinib exposure was almost
achieved, in terms of the required concentration for target
inhibition of ≥50 ng/mL [16].
In summary, the MTD of sunitinib was 25 mg/day on
Schedule 2/2 in combination with cisplatin and S-1 when
administered as a first-line therapy in patients with advanced
or metastatic gastric cancer. This combination had a man-
ageable safety profile and showed preliminary evidence of
antitumor activity.
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